TY - JOUR T1 - Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents JF - medRxiv DO - 10.1101/2021.04.17.21255663 SP - 2021.04.17.21255663 AU - Carolina Garrido AU - Jillian H. Hurst AU - Cynthia G. Lorang AU - Jhoanna N. Aquino AU - Javier Rodriguez AU - Trevor S. Pfeiffer AU - Tulika Singh AU - Eleanor C. Semmes AU - Debra J. Lugo AU - Alexandre T. Rotta AU - Nicholas A. Turner AU - Thomas W. Burke AU - Micah T. McClain AU - Elizabeth A. Petzold AU - Sallie R. Permar AU - M. Anthony Moody AU - Christopher W. Woods AU - Matthew. S. Kelly AU - Genevieve G. Fouda Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/20/2021.04.17.21255663.abstract N2 - As SARS-CoV-2 continues to spread globally, questions have emerged regarding the strength and durability of immune responses in specific populations. In this study, we evaluated humoral immune responses in 69 children and adolescents with asymptomatic or mild symptomatic SARS-CoV-2 infection. We detected robust IgM, IgG, and IgA antibody responses to a broad array of SARS-CoV-2 antigens at the time of acute infection and 2 and 4 months after acute infection in all participants. Notably, these antibody responses were associated with virus neutralizing activity that was still detectable 4 months after acute infection in 94% of children. Moreover, antibody responses and neutralizing activity in sera from children and adolescents were comparable or superior to those observed in sera from 24 adults with mild symptomatic infection. Taken together, these findings indicate children and adolescents with mild or asymptomatic SARS-CoV-2 infection generate robust and durable humoral immune responses that are likely to protect from reinfection.Competing Interest StatementTWB is a consultant for Predigene. CWW reports advisory board fees from Roche Molecular Sciences, non-financial support from bioMérieux and Becton Dickinson, a research collaboration with Biofire, and is co-founder of Predigen. MSK reports advisory board feeds from Adagio Therapeutics, Inc. All other authors have no competing interests to declare.Funding StatementThis work was funded by the Duke University School of Medicine and through grants from the Duke Microbiome Center, Children's Miracle Network Hospitals, and the Translating Duke Health Children's Health and Discovery Initiative. Additional support was provided by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, NIH/NIAID (U01AI066569, UM1AI104681), the U.S. Defense Advanced Projects Agency (DARPA, N66001-09-C-2082 and HR0011-17-2-0069), and Virology Quality Assurance (VQA) # 75N93019C00015. COVID-19 samples were processed under BSL2 with aerosol management enhancement or BSL3 in the Duke Regional Biocontainment Laboratory which received partial support for construction from NIH/NIAID (UC6AI058607). MSK was supported by a NIH Career Development Award (K23-AI135090). TS was supported by the Duke Global Health Institute Scholars Program. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Duke University Health System (DUHS) Institutional Review Board. Informed consent was obtained from all study participants or their legal guardians, with written approval obtained using an electronic consent document.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request to the authors. ER -